Clinical trial
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00282048 |
|---|---|
| Title | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer |
| Official title | Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Neoplasms, Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | AG-013736 (axitinib) |
| Enrollment | 62 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 25, 2006 |
| Last update posted | Jul 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: